Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms

European Archives of Psychiatry and Clinical Neuroscience

Volumn 257, Issue 6, 2007, Pages 360-370

  Riedel, Michael ^a   Spellmann, Ilja ^a   Strassnig, Martin ^b   Douhet, Anette ^a   Dehning, Sandra ^a   Opgen Rhein, Markus ^a   Valdevit, Rosamaria ^a   Engel, Rolf R ^a   Kleindienst, Nikolaus ^a   Müller, Norbert ^a   Möller, Hans Jürgen ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Atypical antipsychotics; Cognitive improvement; Parallel group study; Randomised clinical study

Indexed keywords

BIPERIDEN; LORAZEPAM; QUETIAPINE; RISPERIDONE; ZOPICLONE;

ADULT; AKATHISIA; ARTICLE; ATTENTION; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; HUMAN; INSOMNIA; NAUSEA; PARKINSONISM; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCALE FOR THE ASSESSMENT OF NEGATIVE SYMPTOM; SCHIZOPHRENIA; SIMPSON ANGUS SCALE; VERBAL MEMORY; WORKING MEMORY;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; ATTENTION; COGNITION; DATA INTERPRETATION, STATISTICAL; DIBENZOTHIAZEPINES; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; MEMORY; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; REACTION TIME; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; VERBAL LEARNING;

EID: 34249876152     PISSN: 09401334     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00406-007-0739-x     Document Type: Article

References (76)

1. Addington J, Addington D, Maticka-Tyndale E (1991) Cognitive functioning and positive and negative symptoms in schizophrenia. Schizophr Res 5:123-134
2. Albus M, Hubmann W, Mohr F, Hecht S, Hinterberger-Weber P, Seitz NN, Kuchenhoff H (2006) Neurocognitive functioning in patients with first-episode schizophrenia: results of a prospective 5-year follow-up study. Eur Arch Psychiatry Clin Neurosci 256:442-451
3. Arvanitis LA, Miller BG (1997) Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 42:233-246
4. Beasley CM Jr, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S (1996) Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 14:111-123
5. Berman I, Viegner B, Merson A, Allan E, Pappas D, Green AI (1997) Differential relationships between positive and negative symptoms and neuropsychological deficits in schizophrenia. Schizophr Res 25:1-10
6. Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, Sheitman B, Lindenmayer JP, Citrome L, McEvoy J, Kunz M, Chakos M, Cooper TB, Horowitz TL, Lieberman JA (2002) Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 159:1018-1028
7. Bleuler E (1950) Dementia praecox for the group of schizophrenias. Zinkin J (ed). International University Press, New York
8. Capleton RA (1996) Cognitive function in schizophrenia: association with negative and positive symptoms. Psychol Rep 78:123-128
9. Carman J, Peuskens J, Vangeneugden A (1995) Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis. Int Clin Psychopharmacol 10:207-213
10. Chouinard G (1995) Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. J Clin Psychopharmacol 15(Suppl 1):36S-44S
11. Dickerson F, Boronow JJ, Ringel N, Parente F (1996) Neurocognitive deficits and social functioning in outpatients with schizophrenia. Schizophr Res 21:75-83
12. Fenton WS, McGlashan TH (1991) Natural history of schizophrenia subtypes. II. Positive and negative symptoms and long-term course. Arch Gen Psychiatry 48:978-986
13. Fujii DE, Wylie AM, Nathan JH (2004) Neurocognition and long-term prediction of quality of life in outpatients with severe and persistent mental illness. Schizophr Res 69:67-73
14. Gelenberg AJ, Van Putten T, Lavori PW, Wojcik JD, Falk WE, Marder S, Galvin-Nadeau M, Spring B, Mohs RC, Brotman AW (1989) Anticholinergic effects on memory: benztropine versus amantadine. J Clin Psychopharmacol 9:180-185
15. Gold JM, Carpenter C, Randolph C, Goldberg TE, Weinberger DR (1997) Auditory working memory and the Wisconsin Card Sorting Test. Arch Gen Psychiatry 54:159-168
16. Goldberg TE, Greenberg RD, Griffin SJ, Gold JM, Kleinman JE, Pickar D, Schulz SC, Weinberger DR (1993) The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br J Psychiatry 162:43-48
17. Goldstein G, Allen DN, Seaton BE (1998) A comparison of clustering solutions for cognitive heterogeneity in schizophrenia. J Int Neuropsychol Soc 4:353-362
18. Gonzalez-Blanch C, Alvarez-Jimenez M, Rodriguez-Sanchez JM, Perez-Iglesias R, Vazquez-Barquero JL, Crespo-Facorro B (2006) Cognitive functioning in the early course of first-episode schizophrenia spectrum disorders: timing and patterns. Eur Arch Psychiatry Clin Neurosci 256:364-371
19. Green MF (1996) What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 153:321-330
20. Green MF, Neuchterlein KH (1999) Should schizophrenia be treated as a neurocognitive disorder? Schizophr Bull 25:309-319
21. Green MF, Marshall BD Jr, Wirshing WC, Ames D, Marder SR, McGurk S, Kern RS, Mintz J (1997) Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry 154:799-804
22. Green MF, Kern RS, Braff DL, Mintz J (2000) Neurocognitive deficits and functional outcome on schizophrenia: are we measuring the 'right stuff'? Schizophr Bull 26:119-136
23. Green MF, Marder SR, Glynn SM, McGurk SR, Wirshing WC, Wirshing DA, Liberman RP, Mintz J (2002) The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone. Biol Psychiatry 51:972-978
24. Gutbrod K, Cohen R, Mager B, Meier E (1989) Coding and recall of categorized material in aphasics. J Clin Exp Neuropsychol 11:821-841
25. Harvey PD, Davidson M, Mueser KT, Parrella M, White L, Powchik P (1997) Social Adaptive Functioning Evaluation (SAFE): a rating scale for geriatric psychiatric patients. Schizophr Bull 23:131-145
26. Harvey PD, Patterson TL, Potter LS, Zhong K, Brecher M (2006) Improvement in social competence with short-term atypical antipsychotic treatment: a randomized, double-blind comparison of quetiapine versus risperidone for social competence, social cognition, and neuropsychological functioning. Am J Psychiatry 163:1918-1925
27. Hawkins KA (1999) Memory deficits in patients with schizophrenia: preliminary data from the Wechsler Memory Scale-Third Edition support earlier findings. J Psychiatry Neurosci 24:341-347
28. Hawkins KA, Hoffman RE, Quinlan DM, Rakfeldt J, Docherty NM, Sledge WH (1997) Cognition, negative symptoms, and diagnosis: a comparison of schizophrenic, bipolar, and control samples. J Neuropsychiatry Clin Neurosci 9:81-89
29. Heaton RK, Gladsjo JA, Palmer BW, Kuck J, Marcotte TD, Jeste DV (2001) Stability and course of neuropsychological deficits in schizophrenia. Arch Gen Psychiatry 58:24-32
30. Heydebrand G, Weiser M, Rabinowitz J, Hoff AL, DeLisi LE, Csernansky JG (2004) Correlates of cognitive deficits in first episode schizophrenia. Schizophr Res 68:1-9
31. Hogarty GE, Flesher S, Ulrich R, Carter M, Greenwald D, Pogue-Geile M, Kechavan M, Cooley S, DiBarry AL, Garrett A, Parepally H, Zoretich R (2004) Cognitive enhancement therapy for schizophrenia: effects of a 2-year randomized trial on cognition and behavior. Arch Gen Psychiatry 61:866-876
32. Hwu HG, Chen CH, Hwang TJ, Liu CM, Cheng JJ, Lin SK, Liu SK, Chen Ch, Chi YY, Ou-Young CW, Lin HN, Chen WJ (2002) Symptom patterns and subgrouping of schizophrenic patients: significance of negative symptoms assessed on admission. Schizophr Res 56:105-119
33. Ichikawa J, Dai J, O'Laughlin IA, Fowler WL, Meltzer HY (2002) Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology 26:325-339
34. Kane J, Honigfeld G, Singer J, Meltzer H (1988) Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789-796
35. Kapur S, Seeman P (2000) Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action. J Psychiatry Neurosci 25:161-166
36. Kapur S, Seeman P (2001) Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis. Am J Psychiatry 158:360-369
37. Kasper S, Tauscher J, Kufferle B, Barnas C, Pezawas L, Quiner S (1999) Dopamine- and serotonin-receptors in schizophrenia: results of imaging studies and implications for pharmacotherapy in schizophrenia. Eur Arch Psychiatry Clin Neurosci 249(Suppl 4):83-89
38. Keefe R, Roitman S, Harvey PD, Blum CS, DuPre RL, Prieto DM, Davidson M, Davos KL (1995) A pen-and-paper human analogue of a monkey prefrontal cortex activation task: spatial working memory in patients with schizophrenia. Schizophr Res 17:25-33
39. Keefe RS, Silva SG, Perkins DO, Lieberman JA (1999) The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 25:201-222
40. Keefe RS, Seidman LJ, Christensen BK, Hamer RM, Sharma T, Sitskoorn MM, Lewine RR, Yurgelun-Todd DA, Gur RC, Tohen M, Tollefson GD, Sanger TM, Lieberman JA (2004) Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry 161:985-995
41. Keefe RS, Seidman LJ, Christensen BK, Hamer RM, Sharma T, Sitskoorn MM, Rock SL, Woolson S, Tohen M, Tollefson GD, Sanger TM, Lieberman JA, HGDH Research Group (2006) Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis. Biol Psychiatry 59:97-105
42. Keefe RS, Young CA, Rock SL, Purdon SE, Gold JM, Breier A, HGGN Study Group (2006) One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. Schizophr Res 81:1-15
43. Keshavan MS (1999) Development, disease and degeneration in schizophrenia: a unitary pathophysiological model. J Psychiatr Res 33:513-521
44. Kirkpatrick B, Fenton WS, Carpenter WT Jr, Marder SR (2006) The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull 32:214-219
45. Klosterkötter J (1990) Minussymptomatik und kognitive Basissymptome. In: Möller HJ, Pelzer E (eds) Neuere Ansätze zur Diagnostik und Therapie schizophrener Minussymptomatik. Springer, Berlin, Heidelberg, New York, pp 15-24
46. Kraepelin E (1919) Dementia praecox and paraphrenia. Barclay RM, Robertson GM (eds). Livingstone, Edinburgh
47. Lehrl S (1977) Mehrfachwahl-Wortschatz-Intellingenztest. Manual zum MWT-B. Straube, Erlangen
48. Leucht S, Pitschel-Walz G, Abraham D, Kissling W (1999) Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 35:51-68
49. Leucht S, Wahlbeck K, Hamann J, Kissling W (2003) New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 361:1581-1589
50. Lewis R (2004) Should cognitive deficit be a diagnostic criterion for schizophrenia? J Psychiatry Neurosci 29:102-113
51. Lieberman JA, Safferman AZ, Pollack S, Szymanski S, Johns C, Howard A, Kronig M, Bookstein P, Kane JM (1994) Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry 151:1744-1752
52. McGrath J, Emmerson WB (1999) Fortnightly review. Treatment of schizophrenia. BMJ 319:1045-1048
53. Meltzer HY (2004) Cognitive factors in schizophrenia: causes, impact, and treatment. CNS Spectr 9:15-24
54. Möller HJ (1995) The negative component in schizophrenia. Acta Psychiatr Scand 388:11-14
55. Mullen J, Jibson M, Sweitzer D (2001) Comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the Quetiapine Experience with Safety and Tolerability (QUEST) study. Clin Ther 23:1839-1854
56. Murphy BP, Chung YC, Park TW, McGorry PD (2006) Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review. Schizophr Res 88:5-25
57. Nasrallah HA, Tandon R (2002) Efficacy, safety, and tolerability of quetiapine in patients with schizophrenia. J Clin Psychiatry 63(Suppl 13):12-20
58. Palmer BW, Heaton RK, Paulsen JS, Kuck J, Braff D, Harris MJ, Zisook S, Jeste DV (1997) Is it possible to be schizophrenic yet neuropsychologically normal? Neuropsychology 11:437-446
59. Peuskens J, Demily C, Thibaut F (2005) Treatment of cognitive dysfunction in schizophrenia. Clin Ther 27:25-37
60. Reitan RM (1958) Validity of the trailmaking test as an indication of organic brain damage. Percept Motor Skills 8:271-276
61. Remington G, Kapur S (2000) Atypical antipsychotics: are some more atypical than others? Psychopharmacology 148:315
62. Rey A (1958) L'examen clinique en psychologie. Presse Universitaire de France, Paris
63. Riedel M, Muller N, Strassnig M, Spellmann I, Engel RR, Musil R, Dehning S, Douhet A, Schwarz MJ, Möller HJ (2005) Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms. Eur Arch Psychiatry Clin Neurosci 255:432-437
64. Schuepbach D, Hill SK, Sanders RD, Hell D, Keshavan MS, Sweeney JA (2004) Early treatment-induced improvement of negative symptoms predicts cognitive functioning in treatment-naive first episode schizophrenia: a 2-year follow up. Schizophr Bull 30:837-848
65. Spohn HE, Strauss ME (1989) Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. J Abnorm Psychol 98:367-380
66. Spreen O, Benton AL (1965) Comparative studies of some psychological tests for cerebral damage. J Nerv Ment Dis 140:323-333
67. Tamminga CA, Buchanan RW, Gold JM (1998) The role of negative symptoms and cognitive dysfunction in schizophrenia outcome. Int Clin Psychopharmacol 13(Suppl 3):S21-S26
68. Velligan DI, Mahurin RK, Diamond PL, Hazelton BC, Eckert SL, Miller AL (1997) The functional significance of symptomatology and cognitive function in schizophrenia. Schizophr Res 25:21-31
69. Velligan DI, Bow-Thomas CC, Mahurin RK, Miller AL, Halgunseth LC (2000) Do specific neurocognitive deficits predict specific domains of community function in schizophrenia? J Nerv Ment Dis 188:518-524
70. Velligan DI, Prihoda TJ, Sui D, Ritch JL, Maples N, Miller AL (2003) The effectiveness of quetiapine versus conventional antipsychotics in improving cognitive and functional outcomes in standard treatment settings. J Clin Psychiatry 64:524-531
71. Voruganti LN, Heslegrave RJ, Awad AG (1997) Neurocognitive correlates of positive and negative syndromes in schizophrenia. Can J Psychiatry 42:1066-1071
72. Wagner M, Quednow BB, Westheide J, Schlaepfer TE, Maier W, Kuhn KU (2005) Cognitive improvement in schizophrenic patients does not require a serotonergic mechanism: randomized controlled trial of olanzapine vs. amisulpride. Neuropsychopharmacology 30:381-390
73. Walker EF (1985) Validating and conceptualizing positive and negative symptoms. In: Harvey PD, Walker EF (eds) Positive and negative symptoms of psychosis. Hillsdale, New York
74. Walker E, Harvey P (1986) Positive and negative symptoms in schizophrenia: attentional performance correlates. Psychopathology 19:294-302
75. Wiebel B, Happe A, Piekara FH (1995) Das neuropsychologische Diagnostikprogramm TESTBAT. PSYMED, Dülmen
76. Zhong KX, Sweitzer DE, Hamer RM, Lieberman JA (2006) Comparison of quetiapine and risperidone in the treatment of schizophrenia: a randomized, double-blind, flexible-dose, 8-week study. J Clin Psychiatry 67:1093-1103